Compare Deutsche Bank AG (DB) vs Iovance Biotherapeutics Inc. Common Stock (IOVA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Deutsche Bank AG vs Iovance Biotherapeutics Inc. Common Stock — how do they compare? Deutsche Bank AG trades at $33.51 (market cap $62.42B), while Iovance Biotherapeutics Inc. Common Stock trades at $13.89 (market cap $6.04B). The key difference: Deutsche Bank AG is far larger — about 10.3× Iovance Biotherapeutics Inc. Common Stock's market cap, and Deutsche Bank AG pays a 3.46% dividend while Iovance Biotherapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Deutsche Bank AG for 80 Days and Iovance Biotherapeutics Inc. Common Stock for 0 Days on average.
| DB | IOVA | |
|---|---|---|
Market Cap | $62.42B | $6.04B |
Volume | 2,918,760 | 14,805,993 |
Sector | Financials | Health |
52-Week High | $41.56 | $14.82 |
52-Week Low | $28.37 | $1.81 |
Typical Hold Time | 80 Days | 0 Days |
Enterprise Value | $77.06B | $5.97B |
Dividend Yield | 3.46% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Deutsche Bank (DB) trades at $33.55, down 4.5% on concerns about Q3 investment banking revenue. The stock shows attractive valuation metrics with P/E of 9.09 and P/B of 0.71, while fundamentals improved with 2025 net income reaching $6.93B and profit margin expanding to 21.59%. Technical indicators signal bearish momentum with the price near key support at $33. Recent news highlights the bank's strategic focus on wealth management growth and 2028 return targets.
The outlook remains balanced - strong fundamentals and undervaluation provide upside potential, but near-term headwinds in investment banking and technical weakness suggest cautious optimism. Key risks include execution on strategic targets and market-sensitive revenue streams, while analyst consensus leans neutral with 58% hold ratings.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Deutsche Bank AG
In July 2019, Deutsche Bank announced another restructuring plan hoping to revitalize revenue, reduce costs, and return to profitability. The largest moving pieces of the new plan is the full exit of global equity sales & trading, the scaling back of its fixed income business, as well as 18,000 FTE reductions until 2022. The remaining core business segments include private banking, corporate banking, asset management, and investment banking.
Read more on DB →About Iovance Biotherapeutics Inc. Common Stock
Iovance Biotherapeutics develops cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes, or TIL, to target solid tumors.
Read more on IOVA →
